ID   FGFR3_HUMAN             Reviewed;         806 AA.
AC   P22607; Q14308; Q16294; Q16608;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   02-NOV-2010, entry version 148.
DE   RecName: Full=Fibroblast growth factor receptor 3;
DE            Short=FGFR-3;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD333;
DE   Flags: Precursor;
GN   Name=FGFR3; Synonyms=JTK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=91142118; PubMed=1847508; DOI=10.1073/pnas.88.4.1095;
RA   Keegan K., Johnson D.E., Williams L.T., Hayman M.J.;
RT   "Isolation of an additional member of the fibroblast growth factor
RT   receptor family, FGFR-3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:1095-1099(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   MEDLINE=21561228; PubMed=11703096; DOI=10.1006/mcbr.2001.0306;
RA   Terada M., Shimizu A., Sato N., Miyakaze S.I., Katayama H.,
RA   Kurokawa-Seo M.;
RT   "Fibroblast growth factor receptor 3 lacking the Ig IIIb and
RT   transmembrane domains secreted from human squamous cell carcinoma DJM-
RT   1 binds to FGFs.";
RL   Mol. Cell Biol. Res. Commun. 4:365-373(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-65; LEU-384;
RP   THR-441; THR-717 AND PHE-726.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   MEDLINE=92147110; PubMed=1664411; DOI=10.1016/0888-7543(91)90041-C;
RA   Thompson L.M., Plummer S., Schalling M., Altherr M.R., Gusella J.F.,
RA   Housman D.E., Wasmuth J.J.;
RT   "A gene encoding a fibroblast growth factor receptor isolated from the
RT   Huntington disease gene region of human chromosome 4.";
RL   Genomics 11:1133-1142(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 614-681.
RX   MEDLINE=91062389; PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Colon tumor;
RX   MEDLINE=95007529; PubMed=7923141;
RA   Murgue B., Tsunekawa S., Rosenberg I., deBeaumont M., Podolsky D.K.;
RT   "Identification of a novel variant form of fibroblast growth factor
RT   receptor 3 (FGFR3 IIIb) in human colonic epithelium.";
RL   Cancer Res. 54:5206-5211(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Keratinocyte;
RX   MEDLINE=96085129; PubMed=7495869; DOI=10.1016/0167-4781(95)00156-B;
RA   Scotet E., Houssaint E.;
RT   "The choice between alternative IIIb and IIIc exons of the FGFR-3 gene
RT   is not strictly tissue-specific.";
RL   Biochim. Biophys. Acta 1264:238-242(1995).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1.
RX   PubMed=14732692; DOI=10.1073/pnas.0307287101;
RA   Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V.,
RA   Yayon A., Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M.;
RT   "Insights into the molecular basis for fibroblast growth factor
RT   receptor autoinhibition and ligand-binding promiscuity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:935-940(2004).
RN   [9]
RP   VARIANT ACH ARG-380.
RX   MEDLINE=94359611; PubMed=8078586; DOI=10.1038/371252a0;
RA   Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.-M.,
RA   Maroteaux P., le Merrer M., Munnich A.;
RT   "Mutations in the gene encoding fibroblast growth factor receptor-3 in
RT   achondroplasia.";
RL   Nature 371:252-254(1994).
RN   [10]
RP   VARIANT ACH ARG-380.
RX   MEDLINE=95150025; PubMed=7847369;
RA   Bellus G.A., Hefferon T.W., de Luna R.I., Hecht J.T., Horton W.A.,
RA   Machado M., Kaitila I., McIntosh I., Francomano C.A.;
RT   "Achondroplasia is defined by recurrent G380R mutations of FGFR3.";
RL   Am. J. Hum. Genet. 56:368-373(1995).
RN   [11]
RP   VARIANT ACH CYS-375.
RX   MEDLINE=95278277; PubMed=7758520; DOI=10.1007/s004310050278;
RA   Superti-Furga A., Eich G., Bucher H.U., Wisser J., Giedion A.,
RA   Gitzelmann R., Steinmann B.;
RT   "A glycine 375-to-cysteine substitution in the transmembrane domain of
RT   the fibroblast growth factor receptor-3 in a newborn with
RT   achondroplasia.";
RL   Eur. J. Pediatr. 154:215-219(1995).
RN   [12]
RP   VARIANT TD CYS-249.
RX   MEDLINE=96154693; PubMed=8589699; DOI=10.1093/hmg/4.11.2175;
RA   Tavormina P.L., Rimoin D.L., Cohn D.H., Zhu Y.-Z., Shiang R.,
RA   Wasmuth J.J.;
RT   "Another mutation that results in the substitution of an unpaired
RT   cysteine residue in the extracellular domain of FGFR3 in thanatophoric
RT   dysplasia type I.";
RL   Hum. Mol. Genet. 4:2175-2177(1995).
RN   [13]
RP   VARIANTS TD CYS-248; CYS-371 AND GLU-650.
RX   MEDLINE=95291326; PubMed=7773297; DOI=10.1038/ng0395-321;
RA   Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.-Z., Wilkin D.J.,
RA   Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J.;
RT   "Thanatophoric dysplasia (types I and II) caused by distinct mutations
RT   in fibroblast growth factor receptor 3.";
RL   Nat. Genet. 9:321-328(1995).
RN   [14]
RP   VARIANT HYPOCHONDROPLASIA LYS-540.
RX   MEDLINE=95400307; PubMed=7670477; DOI=10.1038/ng0795-357;
RA   Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I.,
RA   Horton W.A., Greenhaw G.A., Hecht J.T., Francomano C.A.;
RT   "A recurrent mutation in the tyrosine kinase domain of fibroblast
RT   growth factor receptor 3 causes hypochondroplasia.";
RL   Nat. Genet. 10:357-359(1995).
RN   [15]
RP   VARIANT CAN GLU-391.
RX   MEDLINE=96083601; PubMed=7493034; DOI=10.1038/ng1295-462;
RA   Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W.;
RT   "Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in
RT   Crouzon syndrome with acanthosis nigricans.";
RL   Nat. Genet. 11:462-464(1995).
RN   [16]
RP   CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   MEDLINE=96174812; PubMed=8599935;
RA   Webster M.K., Donoghue D.J.;
RT   "Constitutive activation of fibroblast growth factor receptor 3 by the
RT   transmembrane domain point mutation found in achondroplasia.";
RL   EMBO J. 15:520-527(1996).
RN   [17]
RP   VARIANTS TD CYS-248; CYS-249; CYS-370 AND CYS-373.
RX   MEDLINE=96254981; PubMed=8845844; DOI=10.1093/hmg/5.4.509;
RA   Rousseau F., el Ghouzzi V., Delezoide A.-L., Legeai-Mallet L.,
RA   le Merrer M., Munnich A., Bonaventure J.;
RT   "Missense FGFR3 mutations create cysteine residues in thanatophoric
RT   dwarfism type I (TD1).";
RL   Hum. Mol. Genet. 5:509-512(1996).
RN   [18]
RP   VARIANT MNKS ARG-250.
RX   MEDLINE=97195541; PubMed=9042914;
RA   Muenke M., Gripp K.W., McDonald-Mcginn D.M., Gaudenz K.,
RA   Whitaker L.A., Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N.,
RA   Mulvihill J.J., Losken H.W., Mulliken J.B., Guttmacher A.E.,
RA   Wilroy R.S., Clarke L.A., Hollway G., Ades L.C., Haan E.A.,
RA   Mulley J.C., Cohen M.M. Jr., Bellus G.A., Francomano C.A.,
RA   Moloney D.M., Wall S.A., Wilkie A.O.M., Zackai E.H.;
RT   "A unique point mutation in the fibroblast growth factor receptor 3
RT   gene (FGFR3) defines a new craniosynostosis syndrome.";
RL   Am. J. Hum. Genet. 60:555-564(1997).
RN   [19]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANTS CYS-373; GLU-650 AND
RP   MET-650.
RX   PubMed=9207791; DOI=10.1038/ng0797-260;
RA   Chesi M., Nardini E., Brents L.A., Schroeck E., Ried T., Kuehl W.M.,
RA   Bergsagel P.L.;
RT   "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is
RT   associated with increased expression and activating mutations of
RT   fibroblast growth factor receptor 3.";
RL   Nat. Genet. 16:260-264(1997).
RN   [20]
RP   VARIANT TD CYS-370.
RX   MEDLINE=99004917; PubMed=9790257;
RA   Katsumata N., Kuno T., Miyazaki S., Mikami S., Nagashima-Miyokawa A.,
RA   Nimura A., Horikawa R., Tanaka T.;
RT   "G370C mutation in the FGFR3 gene in a Japanese patient with
RT   thanatophoric dysplasia.";
RL   Endocr. J. 45:S171-S174(1998).
RN   [21]
RP   VARIANT HYPOCHONDROPLASIA VAL-538.
RX   PubMed=10215410;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<333::AID-HUMU17>3.3.CO;2-A;
RA   Grigelioniene G., Hagenaes L., Ekloef O., Neumeyer L., Haereid P.E.,
RA   Anvret M.;
RT   "A novel missense mutation Ile538Val in the fibroblast growth factor
RT   receptor 3 in hypochondroplasia.";
RL   Hum. Mutat. 11:333-333(1998).
RN   [22]
RP   VARIANT HYPOCHONDROPLASIA THR-540.
RX   MEDLINE=98112422; PubMed=9452043;
RA   Deutz-Terlouw P.P., Losekoot M., Aalfs C.M., Hennekam R.C.M.,
RA   Bakker E.;
RT   "Asn540Thr substitution in the fibroblast growth factor receptor 3
RT   tyrosine kinase domain causing hypochondroplasia.";
RL   Hum. Mutat. Suppl. 1:S62-S65(1998).
RN   [23]
RP   VARIANT TD MET-650.
RX   PubMed=10671061;
RA   Kitoh H., Brodie S.G., Kupke K.G., Lachman R.S., Wilcox W.R.;
RT   "Lys650Met substitution in the tyrosine kinase domain of the
RT   fibroblast growth factor receptor gene causes thanatophoric dysplasia
RT   type I.";
RL   Hum. Mutat. 12:362-363(1998).
RN   [24]
RP   VARIANT ARG-250.
RX   PubMed=9525367; DOI=10.1016/S0140-6736(98)24012-8;
RA   Hollway G.E., Suthers G.K., Battese K.M., Turner A.M., David D.J.,
RA   Mulley J.C.;
RT   "Deafness due to Pro250Arg mutation of FGFR3.";
RL   Lancet 351:877-878(1998).
RN   [25]
RP   VARIANTS TD CYS-248; CYS-249 AND CYS-373.
RX   PubMed=10360402;
RX   DOI=10.1002/(SICI)1096-8628(19990611)84:5<476::AID-AJMG12>3.3.CO;2-O;
RA   Brodie S.G., Kitoh H., Lachman R.S., Nolasco L.M., Mekikian P.B.,
RA   Wilcox W.R.;
RT   "Platyspondylic lethal skeletal dysplasia, San Diego type, is caused
RT   by FGFR3 mutations.";
RL   Am. J. Med. Genet. 84:476-480(1999).
RN   [26]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9950359;
RA   Lajeunie E., El Ghouzzi V., Le Merrer M., Munnich A., Bonaventure J.,
RA   Renier D.;
RT   "Sex related expressivity of the phenotype in coronal craniosynostosis
RT   caused by the recurrent P250R FGFR3 mutation.";
RL   J. Med. Genet. 36:9-13(1999).
RN   [27]
RP   VARIANTS BLADDER AND CERVIX CANCERS CYS-248; CYS-249; CYS-370 AND
RP   GLU-650.
RX   MEDLINE=99400545; PubMed=10471491; DOI=10.1038/12615;
RA   Cappellen D., De Oliveira C., Ricol D., Gil Diez de Medina S.,
RA   Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F.;
RT   "Frequent activating mutations of FGFR3 in human bladder and cervix
RT   carcinomas.";
RL   Nat. Genet. 23:18-20(1999).
RN   [28]
RP   VARIANT HYPOCHONDROPLASIA GLN-650.
RX   MEDLINE=20530223; PubMed=11055896; DOI=10.1086/316892;
RA   Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T.,
RA   Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J.,
RA   Francomano C.A.;
RT   "Distinct missense mutations of the FGFR3 Lys650 codon modulate
RT   receptor kinase activation and the severity of the skeletal dysplasia
RT   phenotype.";
RL   Am. J. Hum. Genet. 67:1411-1421(2000).
RN   [29]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=10777366; DOI=10.1136/jmg.37.3.220;
RA   Mortier G., Nuytinck L., Craen M., Renard J.-P., Leroy J.G.,
RA   De Paepe A.;
RT   "Clinical and radiographic features of a family with hypochondroplasia
RT   owing to a novel asn540ser mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   J. Med. Genet. 37:220-224(2000).
RN   [30]
RP   VARIANT MNKS ARG-250.
RX   PubMed=11746040; DOI=10.1002/ajmg.10049;
RA   Lowry R.B., Jabs E.W., Graham G.E., Gerritsen J., Fleming J.;
RT   "Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and
RT   sprengel shoulder with and without Pro250Arg mutation in the FGFR3
RT   gene.";
RL   Am. J. Med. Genet. 104:112-119(2001).
RN   [31]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANT CYS-248.
RX   PubMed=11529856; DOI=10.1046/j.1365-2141.2001.02957.x;
RA   Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T.,
RA   Neri A.;
RT   "Analysis of FGFR3 gene mutations in multiple myeloma patients with
RT   t(4;14).";
RL   Br. J. Haematol. 114:362-364(2001).
RN   [32]
RP   VARIANT COLORECTAL CANCER LYS-322.
RX   PubMed=11325814;
RA   Jang J.-H., Shin K.-H., Park J.-G.;
RT   "Mutations in fibroblast growth factor receptor 2 and fibroblast
RT   growth factor receptor 3 genes associated with human gastric and
RT   colorectal cancers.";
RL   Cancer Res. 61:3541-3543(2001).
RN   [33]
RP   VARIANT BLADDER CANCER GLN-650.
RX   PubMed=11314002; DOI=10.1038/sj.onc.1204110;
RA   Sibley K., Cuthbert-Heavens D., Knowles M.A.;
RT   "Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in
RT   transitional cell carcinoma.";
RL   Oncogene 20:686-691(2001).
RN   [34]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=12707965; DOI=10.1002/ajmg.a.10238;
RA   Thauvin-Robinet C., Faivre L., Lewin P., De Monleon J.-V.,
RA   Francois C., Huet F., Couailler J.-F., Campos-Xavier A.B.,
RA   Bonaventure J., Le Merrer M.;
RT   "Hlypochondroplasia and stature within normal limits: another family
RT   with an Asn540-to-Ser mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   Am. J. Med. Genet. A 119:81-84(2003).
RN   [35]
RP   VARIANTS KERSEB CYS-248; CYS-249; CYS-370; CYS-371; CYS-373; GLU-650
RP   AND MET-650.
RX   PubMed=15772091; DOI=10.1093/hmg/ddi127;
RA   Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M.,
RA   Ribeiro A., Gasc J.-M., Jorcano J., Werner S., Sastre-Garau X.,
RA   Thiery J.P., Radvanyi F.;
RT   "Activating mutations of the tyrosine kinase receptor FGFR3 are
RT   associated with benign skin tumors in mice and humans.";
RL   Hum. Mol. Genet. 14:1153-1160(2005).
RN   [36]
RP   VARIANT CATSHL SYNDROME HIS-621.
RX   PubMed=17033969; DOI=10.1086/508433;
RA   Toydemir R.M., Brassington A.E., Bayrak-Toydemir P., Krakowiak P.A.,
RA   Jorde L.B., Whitby F.G., Longo N., Viskochil D.H., Carey J.C.,
RA   Bamshad M.J.;
RT   "A novel mutation in FGFR3 causes camptodactyly, tall stature, and
RT   hearing loss (CATSHL) syndrome.";
RL   Am. J. Hum. Genet. 79:935-941(2006).
RN   [37]
RP   VARIANTS KERATINOCYTIC NON-EPIDERMOLYTIC NEVUS CYS-248; CYS-370 AND
RP   ARG-380.
RX   PubMed=16841094; DOI=10.1172/JCI28163;
RA   Hafner C., van Oers J.M.M., Vogt T., Landthaler M., Stoehr R.,
RA   Blaszyk H., Hofstaedter F., Zwarthoff E.C., Hartmann A.;
RT   "Mosaicism of activating FGFR3 mutations in human skin causes
RT   epidermal nevi.";
RL   J. Clin. Invest. 116:2201-2207(2006).
RN   [38]
RP   VARIANT LADDS ASN-513.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G.,
RA   Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M.,
RA   Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J.,
RA   Yueksel-Apak M., Nuernberg P., Kubisch C., Schlessinger J.,
RA   van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD
RT   syndrome.";
RL   Nat. Genet. 38:414-417(2006).
RN   [39]
RP   VARIANT CAN GLU-391.
RX   PubMed=17935505; DOI=10.1111/j.1399-0004.2007.00884.x;
RA   Arnaud-Lopez L., Fragoso R., Mantilla-Capacho J., Barros-Nunez P.;
RT   "Crouzon with acanthosis nigricans. Further delineation of the
RT   syndrome.";
RL   Clin. Genet. 72:405-410(2007).
RN   [40]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384;
RP   ASN-646 AND GLU-650.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor for acidic and basic fibroblast growth factors.
CC       Preferentially binds FGF1.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-348399, EBI-348399;
CC       P05230:FGF1; NbExp=2; IntAct=EBI-348399, EBI-698068;
CC       Q9Y4H4:GPSM3; NbExp=1; IntAct=EBI-348399, EBI-347538;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=IIIc;
CC         IsoId=P22607-1; Sequence=Displayed;
CC       Name=2; Synonyms=IIIb;
CC         IsoId=P22607-2; Sequence=VSP_002988;
CC       Name=3;
CC         IsoId=P22607-3; Sequence=VSP_002989;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, kidney and testis. Very
CC       low or no expression in spleen, heart, and muscle. In 20- to 22-
CC       week old fetuses it is expressed at high level in kidney, lung,
CC       small intestine and brain, and to a lower degree in spleen, liver,
CC       and muscle. Isoform 2 is detected in epithelial cells. Isoform 1
CC       is not detected in epithelial cells. Isoform 1 and isoform 2 are
CC       detected in fibroblastic cells.
CC   -!- DISEASE: Defects in FGFR3 are the cause of achondroplasia (ACH)
CC       [MIM:100800]. ACH is an autosomal dominant disease and is the most
CC       frequent form of short-limb dwarfism. It is characterized by a
CC       long, narrow trunk, short extremities, particularly in the
CC       proximal (rhizomelic) segments, a large head with frontal bossing,
CC       hypoplasia of the midface and a trident configuration of the
CC       hands.
CC   -!- DISEASE: Defects in FGFR3 are the cause of Crouzon syndrome with
CC       acanthosis nigricans (CAN) [MIM:612247]. Classic Crouzon disease
CC       which is caused by mutations in the FGFR2 gene is characterized by
CC       craniosynostosis (premature fusion of the skull sutures), and
CC       facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a
CC       skin disorder characterized by pigmentation anomalies), CAN, is
CC       considered to be an independant disorder from classic Crouzon
CC       syndrome. CAN is characterized by additional more severe physical
CC       manifestation, such as Chiari malformation, hydrocephalus, and
CC       atresia or stenosis of the choanas, and is caused by a specific
CC       mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It
CC       is proposed to have an autosomal dominant mode of inheritance.
CC   -!- DISEASE: Defects in FGFR3 are a cause of thanatophoric dysplasia
CC       type (TD) [MIM:187600, 187601]; also known as thanatophoric
CC       dwarfism or platyspondylic lethal skeletal dysplasia Sand Diego
CC       type (PLSD-SD). TD is the most common neonatal lethal skeletal
CC       dysplasia. Affected individuals display features similar to those
CC       seen in homozygous achondroplasia. It causes severe shortening of
CC       the limbs with macrocephaly, narrow thorax and short ribs. In the
CC       most common subtype, TD1, femur are curved, while in TD2, straight
CC       femurs are associated with cloverleaf skull. Mutations affecting
CC       different functional domains of FGFR3 cause different forms of
CC       this lethal disorder.
CC   -!- DISEASE: Defects in FGFR3 are a cause of hypochondroplasia (HCH)
CC       [MIM:146000]. HCH is an autosomal dominant disease and is
CC       characterized by disproportionate short stature. It resembles
CC       achondroplasia, but with a less severe phenotype.
CC   -!- DISEASE: Defects in FGFR3 are a cause of susceptibility to bladder
CC       cancer (BLC) [MIM:109800]. A malignancy originating in tissues of
CC       the urinary bladder. It often presents with multiple tumors
CC       appearing at different times and at different sites in the
CC       bladder. Most bladder cancers are transitional cell carcinomas.
CC       They begin in cells that normally make up the inner lining of the
CC       bladder. Other types of bladder cancer include squamous cell
CC       carcinoma (cancer that begins in thin, flat cells) and
CC       adenocarcinoma (cancer that begins in cells that make and release
CC       mucus and other fluids). Bladder cancer is a complex disorder with
CC       both genetic and environmental influences. Note=Somatic mutations
CC       can constitutively activate FGFR3.
CC   -!- DISEASE: Defects in FGFR3 are a cause of cervical cancer (CERCA)
CC       [MIM:603956]. A malignant neoplasm of the cervix, typically
CC       originating from a dysplastic or premalignant lesion previously
CC       present at the active squamocolumnar junction. The transformation
CC       from mild dysplastic to invasive carcinoma generally occurs slowly
CC       within several years, although the rate of this process varies
CC       widely. Carcinoma in situ is particularly known to precede
CC       invasive cervical cancer in most cases. Cervical cancer is
CC       strongly associated with infection by oncogenic types of human
CC       papillomavirus.
CC   -!- DISEASE: Defects in FGFR3 are the cause of camptodactyly tall
CC       stature and hearing loss syndrome (CATSHL syndrome) [MIM:610474].
CC       CATSHL syndrome is an autosomal dominant syndrome characterized by
CC       permanent and irreducible flexion of one or more fingers of the
CC       hand and/or feet, tall stature, scoliosis and/or a pectus
CC       excavatum, and hearing loss. Affected individuals have
CC       developmental delay and/or mental retardation, and several of
CC       these have microcephaly. Radiographic findings included tall
CC       vertebral bodies with irregular borders and broad femoral
CC       metaphyses with long tubular shafts. On audiological exam, each
CC       tested member have bilateral sensorineural hearing loss and absent
CC       otoacoustic emissions. The hearing loss was congenital or
CC       developed in early infancy, progressed variably in early
CC       childhood, and range from mild to severe. Computed tomography and
CC       magnetic resonance imaging reveal that the brain, middle ear, and
CC       inner ear are structurally normal.
CC   -!- DISEASE: Defects in FGFR3 are a cause of multiple myeloma (MM)
CC       [MIM:254500]. MM is a malignant tumor of plasma cells usually
CC       arising in the bone marrow and characterized by diffuse
CC       involvement of the skeletal system, hyperglobulinemia, Bence-Jones
CC       proteinuria and anemia. Complications of multiple myeloma are bone
CC       pain, hypercalcemia, renal failure and spinal cord compression.
CC       The aberrant antibodies that are produced lead to impaired humoral
CC       immunity and patients have a high prevalence of infection.
CC       Amyloidosis may develop in some patients. Multiple myeloma is part
CC       of a spectrum of diseases ranging from monoclonal gammopathy of
CC       unknown significance (MGUS) to plasma cell leukemia. Note=A
CC       chromosomal aberration involving FGFR3 is found in multiple
CC       myeloma. Translocation t(4;14)(p16.3;q32.3) with the IgH locus.
CC   -!- DISEASE: Defects in FGFR3 are a cause of lacrimo-auriculo-dento-
CC       digital syndrome (LADDS) [MIM:149730]; also known as Levy-
CC       Hollister syndrome. LADDS is a form of ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of
CC       two or more ectodermal structures. LADDS is an autosomal dominant
CC       syndrome characterized by aplastic/hypoplastic lacrimal and
CC       salivary glands and ducts, cup-shaped ears, hearing loss,
CC       hypodontia and enamel hypoplasia, and distal limb segments
CC       anomalies. In addition to these cardinal features, facial
CC       dysmorphism, malformations of the kidney and respiratory system
CC       and abnormal genitalia have been reported. Craniosynostosis and
CC       severe syndactyly are not observed.
CC   -!- DISEASE: Defects in FGFR3 are a cause of keratinocytic non-
CC       epidermolytic nevus [MIM:162900]; also known as pigmented moles.
CC       Epidermal nevi of the common, non-organoid and non-epidermolytic
CC       type are benign skin lesions and may vary in their extent from a
CC       single (usually linear) lesion to widespread and systematized
CC       involvement. They may be present at birth or develop early during
CC       childhood.
CC   -!- DISEASE: Defects in FGFR3 are a cause of Muenke syndrome (MNKS)
CC       [MIM:602849]; also known as Muenke non-syndromic coronal
CC       craniosynostosis. MNKS is a condition characterized by premature
CC       closure of coronal suture of skull during development (coronal
CC       craniosynostosis), which affects the shape of the head and face.
CC       It may be uni- or bilateral. When bilateral, it is characterized
CC       by a skull with a small antero-posterior diameter (brachycephaly),
CC       often with a decrease in the depth of the orbits and hypoplasia of
CC       the maxillae. Unilateral closure of the coronal sutures leads to
CC       flattening of the orbit on the involved side (plagiocephaly). The
CC       intellect is normal. In addition to coronal craniosynostosis some
CC       affected individuals show skeletal abnormalities of hands and
CC       feet, sensorineural hearing loss, mental retardation and
CC       respiratory insufficiency.
CC   -!- DISEASE: Defects in FGFR3 are a cause of keratosis seborrheic
CC       (KERSEB) [MIM:182000]. A common benign skin tumor. Seborrheic
CC       keratoses usually begin with the appearance of one or more sharply
CC       defined, light brown, flat macules. The lesions may be sparse or
CC       numerous. As they initially grow, they develop a velvety to finely
CC       verrucous surface, followed by an uneven warty surface with
CC       multiple plugged follicles and a dull or lackluster appearance.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC   -!- SIMILARITY: Contains 3 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR99.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/FGFR3";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M58051; AAA52450.1; -; mRNA.
DR   EMBL; AF245114; AAF63380.1; -; mRNA.
DR   EMBL; AY768549; AAU89726.1; -; Genomic_DNA.
DR   EMBL; M64347; AAA58470.1; -; mRNA.
DR   EMBL; M59374; AAA63209.1; -; mRNA.
DR   EMBL; S76733; AAB33323.1; -; Genomic_DNA.
DR   EMBL; X84939; CAA59334.1; -; mRNA.
DR   EMBL; U22410; AAA67781.1; -; Genomic_DNA.
DR   IPI; IPI00027174; -.
DR   IPI; IPI00220253; -.
DR   IPI; IPI00220254; -.
DR   PIR; A38576; TVHUF3.
DR   RefSeq; NP_000133.1; -.
DR   RefSeq; NP_075254.1; -.
DR   UniGene; Hs.1420; -.
DR   PDB; 1RY7; X-ray; 3.20 A; B=33-365.
DR   PDBsum; 1RY7; -.
DR   ProteinModelPortal; P22607; -.
DR   SMR; P22607; 458-756.
DR   DIP; DIP-4016N; -.
DR   IntAct; P22607; 24.
DR   MINT; MINT-1034697; -.
DR   STRING; P22607; -.
DR   PhosphoSite; P22607; -.
DR   PRIDE; P22607; -.
DR   Ensembl; ENST00000260795; ENSP00000260795; ENSG00000068078.
DR   Ensembl; ENST00000440486; ENSP00000414914; ENSG00000068078.
DR   GeneID; 2261; -.
DR   KEGG; hsa:2261; -.
DR   UCSC; uc003gdr.2; human.
DR   UCSC; uc003gds.2; human.
DR   CTD; 2261; -.
DR   GeneCards; GC04P001762; -.
DR   H-InvDB; HIX0031383; -.
DR   HGNC; HGNC:3690; FGFR3.
DR   HPA; CAB004231; -.
DR   MIM; 100800; phenotype.
DR   MIM; 109800; phenotype.
DR   MIM; 134934; gene.
DR   MIM; 146000; phenotype.
DR   MIM; 149730; phenotype.
DR   MIM; 162900; phenotype.
DR   MIM; 182000; phenotype.
DR   MIM; 187600; phenotype.
DR   MIM; 187601; phenotype.
DR   MIM; 254500; phenotype.
DR   MIM; 602849; phenotype.
DR   MIM; 603956; phenotype.
DR   MIM; 610474; phenotype.
DR   MIM; 612247; phenotype.
DR   Orphanet; 15; Achondroplasia.
DR   Orphanet; 85164; Camptodactyly - tall stature - scoliosis - hearing loss.
DR   Orphanet; 93262; Crouzon syndrome - acanthosis nigricans.
DR   Orphanet; 1555; Cutis gyrata - acanthosis nigricans - craniosynostosis.
DR   Orphanet; 429; Hypochondroplasia.
DR   Orphanet; 35099; Isolated brachycephaly.
DR   Orphanet; 2343; Isolated cloverleaf skull syndrome.
DR   Orphanet; 35098; Isolated plagiocephaly.
DR   Orphanet; 2363; Lacrimo-auriculo-dento-digital syndrome.
DR   Orphanet; 53271; Muenke syndrome.
DR   Orphanet; 794; Saethre-Chotzen syndrome.
DR   Orphanet; 85165; Severe achondroplasia - developmental delay - acanthosis nigricans.
DR   Orphanet; 1860; Thanatophoric dwarfism type I.
DR   Orphanet; 93274; Thanatophoric dwarfism type II.
DR   PharmGKB; PA28129; -.
DR   eggNOG; prNOG16765; -.
DR   HOVERGEN; HBG000345; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; fgf_pathway; FGF signaling pathway.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_9470; Signaling by FGFR.
DR   DrugBank; DB00039; Palifermin.
DR   NextBio; 9179; -.
DR   ArrayExpress; P22607; -.
DR   Bgee; P22607; -.
DR   CleanEx; HS_FGFR3; -.
DR   Genevestigator; P22607; -.
DR   GermOnline; ENSG00000068078; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IPI:MGI.
DR   GO; GO:0005007; F:fibroblast growth factor receptor activity; NAS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016049; P:cell growth; NAS:UniProtKB.
DR   GO; GO:0007259; P:JAK-STAT cascade; TAS:ProtInc.
DR   GO; GO:0000165; P:MAPKKK cascade; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IGI:MGI.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020933; Tyr_kin_fibroblast_GF_rcpt_reg.
DR   InterPro; IPR016248; Tyr_kinase_fibroblast_GF_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 3.
DR   PANTHER; PTHR23256:SF276; Tyr_kinase_fibroblast_GF_rcpt; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Chromosomal rearrangement; Complete proteome; Craniosynostosis;
KW   Deafness; Disease mutation; Disulfide bond; Dwarfism;
KW   Ectodermal dysplasia; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     22
FT   CHAIN        23    806       Fibroblast growth factor receptor 3.
FT                                /FTId=PRO_0000016785.
FT   TOPO_DOM     23    375       Extracellular (Potential).
FT   TRANSMEM    376    396       Helical; (Potential).
FT   TOPO_DOM    397    806       Cytoplasmic (Potential).
FT   DOMAIN       24    126       Ig-like C2-type 1.
FT   DOMAIN      151    244       Ig-like C2-type 2.
FT   DOMAIN      253    355       Ig-like C2-type 3.
FT   DOMAIN      472    761       Protein kinase.
FT   NP_BIND     478    486       ATP (By similarity).
FT   ACT_SITE    617    617       Proton acceptor (By similarity).
FT   BINDING     508    508       ATP (By similarity).
FT   MOD_RES     647    647       Phosphotyrosine (By similarity).
FT   MOD_RES     648    648       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   CARBOHYD     98     98       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    225    225       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    262    262       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    294    294       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    315    315       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    328    328       N-linked (GlcNAc...) (Potential).
FT   DISULFID     61    109       Potential.
FT   DISULFID    176    228       Potential.
FT   DISULFID    275    339       Potential.
FT   VAR_SEQ     311    422       Missing (in isoform 3).
FT                                /FTId=VSP_002989.
FT   VAR_SEQ     311    358       TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHS
FT                                AWLVVLP -> SWISESVEADVRLRLANVSERDGGEYLCRA
FT                                TNFIGVAEKAFWLSVHGPRA (in isoform 2).
FT                                /FTId=VSP_002988.
FT   VARIANT      65     65       G -> R (in dbSNP:rs2305178).
FT                                /FTId=VAR_022167.
FT   VARIANT      79     79       T -> S (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042207.
FT   VARIANT     228    228       C -> R (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042208.
FT   VARIANT     248    248       R -> C (in KERSEB, bladder cancer,
FT                                keratinocytic non-epidermolytic nevus and
FT                                TD; severe and lethal; also found as
FT                                somatic mutation in one patient with
FT                                multiple myeloma).
FT                                /FTId=VAR_004148.
FT   VARIANT     249    249       S -> C (in KERSEB, bladder cancer,
FT                                cervical cancer and TD; type 1).
FT                                /FTId=VAR_004149.
FT   VARIANT     250    250       P -> R (in MNKS; also some individuals
FT                                with autosomal dominant congenital
FT                                sensorineural deafness without
FT                                craniosynostosis; dbSNP:rs4647924).
FT                                /FTId=VAR_004150.
FT   VARIANT     322    322       E -> K (in colorectal cancer).
FT                                /FTId=VAR_018388.
FT   VARIANT     338    338       T -> M.
FT                                /FTId=VAR_042209.
FT   VARIANT     370    370       G -> C (in KERSEB, bladder cancer,
FT                                keratinocytic non-epidermolytic nevus and
FT                                TD; type 1).
FT                                /FTId=VAR_004151.
FT   VARIANT     371    371       S -> C (in KERSEB and TD; type 1).
FT                                /FTId=VAR_004152.
FT   VARIANT     373    373       Y -> C (in KERSEB and TD; type 1).
FT                                /FTId=VAR_004153.
FT   VARIANT     375    375       G -> C (in ACH).
FT                                /FTId=VAR_004154.
FT   VARIANT     380    380       G -> R (in keratinocytic non-
FT                                epidermolytic nevus and ACH; results in
FT                                constitutive activation; very common
FT                                mutation; dbSNP:rs28931614).
FT                                /FTId=VAR_004155.
FT   VARIANT     384    384       F -> L (in dbSNP:rs17881656).
FT                                /FTId=VAR_022168.
FT   VARIANT     391    391       A -> E (in CAN; dbSNP:rs28931615).
FT                                /FTId=VAR_004156.
FT   VARIANT     441    441       A -> T (in dbSNP:rs17884368).
FT                                /FTId=VAR_022169.
FT   VARIANT     513    513       D -> N (in LADDS).
FT                                /FTId=VAR_029887.
FT   VARIANT     538    538       I -> V (in hypochondroplasia).
FT                                /FTId=VAR_004157.
FT   VARIANT     540    540       N -> K (in hypochondroplasia;
FT                                dbSNP:rs28933068).
FT                                /FTId=VAR_004158.
FT   VARIANT     540    540       N -> S (in hypochondroplasia; mild).
FT                                /FTId=VAR_018389.
FT   VARIANT     540    540       N -> T (in hypochondroplasia).
FT                                /FTId=VAR_004159.
FT   VARIANT     621    621       R -> H (in CATSHL syndrome).
FT                                /FTId=VAR_029108.
FT   VARIANT     646    646       D -> N.
FT                                /FTId=VAR_042210.
FT   VARIANT     650    650       K -> E (in KERSEB, TD and bladder cancer
FT                                samples; bladder transitional cell
FT                                carcinoma; somatic mutation).
FT                                /FTId=VAR_004160.
FT   VARIANT     650    650       K -> M (in KERSEB, ACH and TD; type 1).
FT                                /FTId=VAR_004161.
FT   VARIANT     650    650       K -> Q (in hypochondroplasia and bladder
FT                                cancer; in hypochondroplasia the form is
FT                                milder than that seen in individuals with
FT                                the K-540 or M-650 mutations).
FT                                /FTId=VAR_018390.
FT   VARIANT     717    717       A -> T (in dbSNP:rs17882190).
FT                                /FTId=VAR_022170.
FT   VARIANT     726    726       I -> F (in dbSNP:rs17880763).
FT                                /FTId=VAR_022171.
FT   CONFLICT    395    395       L -> V (in Ref. 4; AAA58470).
FT   STRAND      163    167
FT   STRAND      172    175
FT   STRAND      185    187
FT   TURN        208    211
FT   STRAND      212    215
FT   HELIX       220    222
FT   STRAND      226    232
FT   STRAND      235    246
FT   STRAND      263    268
FT   STRAND      271    273
FT   STRAND      283    289
FT   HELIX       293    295
FT   STRAND      302    304
FT   STRAND      324    326
FT   STRAND      335    345
FT   STRAND      348    357
SQ   SEQUENCE   806 AA;  87710 MW;  BC5EA75EA46F447E CRC64;
     MGAPACALAL CVAVAIVAGA SSESLGTEQR VVGRAAEVPG PEPGQQEQLV FGSGDAVELS
     CPPPGGGPMG PTVWVKDGTG LVPSERVLVG PQRLQVLNAS HEDSGAYSCR QRLTQRVLCH
     FSVRVTDAPS SGDDEDGEDE AEDTGVDTGA PYWTRPERMD KKLLAVPAAN TVRFRCPAAG
     NPTPSISWLK NGREFRGEHR IGGIKLRHQQ WSLVMESVVP SDRGNYTCVV ENKFGSIRQT
     YTLDVLERSP HRPILQAGLP ANQTAVLGSD VEFHCKVYSD AQPHIQWLKH VEVNGSKVGP
     DGTPYVTVLK TAGANTTDKE LEVLSLHNVT FEDAGEYTCL AGNSIGFSHH SAWLVVLPAE
     EELVEADEAG SVYAGILSYG VGFFLFILVV AAVTLCRLRS PPKKGLGSPT VHKISRFPLK
     RQVSLESNAS MSSNTPLVRI ARLSSGEGPT LANVSELELP ADPKWELSRA RLTLGKPLGE
     GCFGQVVMAE AIGIDKDRAA KPVTVAVKML KDDATDKDLS DLVSEMEMMK MIGKHKNIIN
     LLGACTQGGP LYVLVEYAAK GNLREFLRAR RPPGLDYSFD TCKPPEEQLT FKDLVSCAYQ
     VARGMEYLAS QKCIHRDLAA RNVLVTEDNV MKIADFGLAR DVHNLDYYKK TTNGRLPVKW
     MAPEALFDRV YTHQSDVWSF GVLLWEIFTL GGSPYPGIPV EELFKLLKEG HRMDKPANCT
     HDLYMIMREC WHAAPSQRPT FKQLVEDLDR VLTVTSTDEY LDLSAPFEQY SPGGQDTPSS
     SSSGDDSVFA HDLLPPAPPS SGGSRT
//
